Biotechnology major Biocon today said it has inked a pact with Quark Pharmaceuticals,Inc to develop a range of siRNA (small interfering RNA) based novel therapeutics.
This collaboration will enable Biocon to co-develop,manufacture and commercialise QPI-1007,a novel siRNA drug candidate for ophthalmic conditions,for India and other key markets, it added.
As part of the agreement,Biocon will have access to Quarks innovative and proprietary siRNA technology platform that can be leveraged for the development of novel therapeutics for various unmet medical needs.
The company,however,did not disclose financial details. Commenting on the development,Biocon chairperson and managing director Kiran Mazumdar Shaw said Quark is the world leader in this technology and their joint development efforts on QPI-1007,targeting ocular neuroprotection,aims at providing relief to several patients suffering from serious ophthalmic conditions.